NSE ScannerMedical Devices & Supplies · Medical Specialties · NSE: LENSKART · data 2026-11-01
Lenskart Solutions Limited
In plain words
Price: 6.5% below its 52-week high of ₹725.
Delivery: 59.1% of traded shares were kept for delivery over the last 10 sessions, against 57.8% over the last 60.
Latest results: a net profit of ₹222 cr for the quarter ended Jun 2026.
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹9,634 cr |
| Net profit (last 12 months) | ₹655 cr |
| Sales growth, 3 years (yearly) | 33.5% |
| Profit growth, 3 years (yearly) | — |
At a glance
Promoters 17.5%, pledged 0.0%, institutions 45.1%.
P/E 179.0, dividend yield 0.0%. Price relative to earnings and book value (low is cheaper, not better).
ROE 6.7%, ROCE 7.8%, operating margin 9.2%: how much profit it earns on the money it uses.
Debt/equity 0.35, Profit growth — and sales growth 33.5% a year over 3 years.
Ratings use fixed thresholds on the latest reported figures. They describe the numbers and are not a recommendation.
Strengths and limitations
None flagged by these rules.
- Low return on equity (6.7%).
- Expensive on earnings (P/E 179.0).
Picked automatically from the latest reported figures with fixed rules; check the company's filings before relying on them.
Latest results in brief (Q1 FY27)
LENSKART Q1 FY27 results (consolidated figures, as filed on NSE).
Revenue was ₹2,714.18 crore, up 7.9% QoQ.
Net profit was ₹221.84 crore, up 10.8% QoQ.
Operating margin was 21.7%.
EPS was ₹1.28, up 9.4% QoQ.
LENSKART के Q1 FY27 नतीजे (कंसोलिडेटेड आंकड़े, NSE पर दाखिल)।
राजस्व: ₹2,714.18 करोड़; पिछली तिमाही की तुलना में 7.9% की बढ़त।
शुद्ध मुनाफ़ा: ₹221.84 करोड़; पिछली तिमाही की तुलना में 10.8% की बढ़त।
ऑपरेटिंग मार्जिन: 21.7%।
EPS: ₹1.28; पिछली तिमाही की तुलना में 9.4% की बढ़त।
LENSKARTના Q1 FY27 પરિણામો (કન્સોલિડેટેડ આંકડા, NSE પર ફાઇલ કરેલા).
આવક (રેવન્યુ): ₹2,714.18 કરોડ; ગયા ક્વાર્ટરની સરખામણીએ 7.9% વધારો.
ચોખ્ખો નફો: ₹221.84 કરોડ; ગયા ક્વાર્ટરની સરખામણીએ 10.8% વધારો.
ઓપરેટિંગ માર્જિન: 21.7%.
EPS: ₹1.28; ગયા ક્વાર્ટરની સરખામણીએ 9.4% વધારો.
Written from the filed numbers. Not a recommendation.
Earnings call in brief (19 Aug 2026)
- Management reported that Q1 FY27 revenue grew 34% year-on-year, PAT grew 182% to ₹ 228 crores, and India same-store sales grew 18.3%.
- Management stated that consolidated product margin crossed 70% for the first time, and international revenue grew 38% with EBITDA pre-Ind AS margin crossing 10% for the first time at ₹ 127 crores.
- Management noted that India revenue grew 30.7% year-on-year to ₹ 1,531 crores, with EBITDA pre-Ind AS 116 margin reaching 15.4% at ₹ 236 crores.
- Management stated that operating cash flow generated was ₹ 297 crores, funding store capex of ₹ 75 crores and plant capex of ₹ 132 crores, leaving a positive net cash inflow of ₹ 116 crores before M&A and equity raise.
- Management mentioned that 63 lakh eye tests were conducted in India in the quarter, with remote optometry now in 786 stores.
- प्रबंधन ने बताया कि वित्त वर्ष 27 की पहली तिमाही में राजस्व सालाना आधार पर 34% बढ़ा, PAT 182% बढ़कर ₹ 228 करोड़ हो गया, और भारत की समान-स्टोर बिक्री 18.3% बढ़ी।
- प्रबंधन ने कहा कि समेकित उत्पाद मार्जिन पहली बार 70% को पार कर गया, और अंतरराष्ट्रीय राजस्व 38% बढ़ा तथा EBITDA पूर्व-Ind AS मार्जिन पहली बार 10% को पार करके ₹ 127 करोड़ हो गया।
- प्रबंधन ने उल्लेख किया कि भारत का राजस्व सालाना आधार पर 30.7% बढ़कर ₹ 1,531 करोड़ हो गया, जिसमें EBITDA पूर्व-Ind AS 116 मार्जिन 15.4% पर पहुंचकर ₹ 236 करोड़ हो गया।
- प्रबंधन ने कहा कि जनरेट किया गया परिचालन नकदी प्रवाह ₹ 297 करोड़ था, जिससे ₹ 75 करोड़ का स्टोर पूंजीगत व्यय (capex) और ₹ 132 करोड़ का प्लांट पूंजीगत व्यय वित्त पोषित हुआ, जिससे M&A और इक्विटी जुटाने से पहले ₹ 116 करोड़ का सकारात्मक शुद्ध नकदी प्रवाह बचा।
- प्रबंधन ने उल्लेख किया कि तिमाही में भारत में 63 लाख आँख की जाँच (eye tests) की गईं, और रिमोट ऑप्टोमेट्री अब 786 स्टोरों में है।
- સંચાલને જણાવ્યું કે Q1 FY27 ની આવક વાર્ષિક ધોરણે 34% વધી, PAT 182% વધીને ₹ 228 કરોડ થઈ, અને ભારતનું સમાન-સ્ટોર્સનું વેચાણ 18.3% વધ્યું.
- સંચાલને જણાવ્યું કે એકત્રિત પ્રોડક્ટ માર્જિન પહેલી વાર 70% વટાવી ગયું, અને આંતરરાષ્ટ્રીય આવક 38% વધી તથા EBITDA પૂર્વ-Ind AS માર્જિન પહેલી વાર 10% વટાવીને ₹ 228 કરોડની જગ્યાએ ₹ 127 કરોડ થયું.
- સંચાલને નોંધ્યું કે ભારતની આવક વાર્ષિક ધોરણે 30.7% વધીને ₹ 1,531 કરોડ થઈ, જેમાં EBITDA પૂર્વ-Ind AS 116 માર્જિન 15.4% પર પહોંચીને ₹ 236 કરોડ થયું.
- સંચાલને જણાવ્યું કે ઉત્પન્ન થયેલ ઓપરેટિંગ કેશ ફ્લો ₹ 297 કરોડ હતો, જેનાથી ₹ 75 કરોડનો સ્ટોર કેપેક્સ અને ₹ 132 કરોડનો પ્લાન્ટ કેપેક્સ ભંડારાયો, જે M&A અને ઇક્વિટી એકત્ર કરતા પહેલા ₹ 116 કરોડનો સકારાત્મક ચોખ્ખો રોકડ પ્રવાહ છોડે છે.
- સંચાલને ઉલ્લેખ કર્યો કે ક્વાર્ટરમાં ભારતમાં 63 લાખ આંખની તપાસ કરવામાં આવી, અને રિમોટ ઓપ્ટોમેટ્રી હવે 786 સ્ટોર્સમાં છે.
What management said on the call, summarised by AI from the official transcript and checked against it. Read the transcript. Not a recommendation.
Smart-money activity
19/100 · Weak over the last ~60 sessions, data 2026-10-30
- Delivery vs usual 0/30: Delivery 54.5% over the last 20 sessions vs 59.5% in the 40 before (0.92x); shares delivered per day 0.34x usual; 0 delivery-spike days (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
- Bulk/block deals 0/20: Net −₹2,390.57 cr in bulk/block deals over 90 days (0 net buying days, 1 net selling day): more sold than bought.
- Insider / SAST buys 0/15: No insider buy or SAST acquisition filings in the last 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 13/15: 33 schemes hold it, about ₹6,335 cr in all (as of 2026-09-30). Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 1/15: Verdict "None", sustained score 28/100.
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Story so far
● Deal ● Results
- 21 Sept 26Deal Bulk deal: PLATINUM JASMINE A 2018 TRUST sold ₹2,390.57 cr -2.2% next session
- 12 Aug 26Results Q1 FY27 results: net profit ₹221.8 cr +1.3% next session
- 20 May 26Results Q4 FY26 results: net profit ₹200.3 cr +1.2% next session
- 11 Feb 26Results Q3 FY26 results: net profit ₹131 cr +7.9% next session
- 29 Nov 25Results Q2 FY26 results: net profit ₹102.2 cr +4.9% next session
From official exchange filings and NSE data. How the price moved after an event describes the past, not what comes next.
Quarterly results (consolidated)
| Quarter | Revenue | Net profit | Profit YoY | Op. margin | EPS ₹ |
|---|---|---|---|---|---|
| Jun 2026 | ₹2,714 cr | ₹222 cr | — | 21.7% | 1.28 |
| Mar 2026 | ₹2,516 cr | ₹200 cr | — | 21.4% | 1.17 |
| Dec 2025 | ₹2,308 cr | ₹131 cr | — | 20.1% | 0.77 |
| Sept 2025 | ₹2,096 cr | ₹102 cr | — | 19.8% | 0.61 |
Shareholding trend
| Holder | Sept 2026 | Jun 2026 | Mar 2026 | Dec 2025 |
|---|---|---|---|---|
| Promoters | 17.52% | 17.53% | 17.55% | 17.57% |
| Foreign institutions (FII) | 18.26% | 12.76% | 4.26% | 3.86% |
| Domestic institutions (DII) | 26.82% | 23.57% | 15.48% | 15.86% |
| Mutual funds | 15.91% | 12.20% | 6.43% | 5.56% |
| Retail investors | 1.15% | 0.77% | 0.56% | 0.60% |
| Number of shareholders | 1,82,996 | 1,35,967 | 1,11,973 | 1,28,502 |
Common questions
What was Lenskart Solutions Limited's latest quarterly profit?
Lenskart Solutions Limited reported a net profit of ₹222 cr for the quarter ended Jun 2026, on revenue of ₹2,714 cr.
How much do promoters hold in Lenskart Solutions Limited?
Promoters held 17.52% of Lenskart Solutions Limited at the end of Sept 2026, with 0.00% of promoter shares pledged.
Is Lenskart Solutions Limited debt-free?
Its latest reported debt-to-equity ratio is 0.35.
What is Lenskart Solutions Limited's P/E ratio?
About 179, based on the last 12 months' earnings and a price of ₹678.2 (data 2026-11-01).
What is the 52-week high and low of Lenskart Solutions Limited?
The 52-week high is ₹725 and the 52-week low is ₹356.1.
Mutual funds holding Lenskart Solutions Limited
From the monthly portfolios of the fund houses the site reads, as of 2026-09-30. 33 schemes holding about ₹6,335 cr; funds that hold it outside their top holdings may not be listed.
| Scheme | Fund house | % of fund | Value |
|---|---|---|---|
| SBI Aggressive Hybrid Fund | SBI Mutual Fund | 1.83% | ₹1,577 cr |
| SBI Focused Fund | SBI Mutual Fund | 2.42% | ₹1,214 cr |
| ADITYA BIRLA SUN LIFE FLEXI CAP FUND | Aditya Birla Sun Life Mutual Fund | 1.90% | ₹532 cr |
| Mirae Asset Large & Midcap Fund | Mirae Asset Mutual Fund | 1.22% | ₹523 cr |
| SBI MultiCap Fund | SBI Mutual Fund | 2.19% | ₹514 cr |
| ADITYA BIRLA SUN LIFE LARGE CAP FUND | Aditya Birla Sun Life Mutual Fund | 1.40% | ₹391 cr |
| Mirae Asset ELSS Tax Saver Fund | Mirae Asset Mutual Fund | 1.41% | ₹347 cr |
| Mirae Asset Midcap Fund | Mirae Asset Mutual Fund | 0.97% | ₹190 cr |
| ADITYA BIRLA SUN LIFE MULTI-CAP FUND | Aditya Birla Sun Life Mutual Fund | 2.31% | ₹167 cr |
| ADITYA BIRLA SUN LIFE CONSUMPTION FUND | Aditya Birla Sun Life Mutual Fund | 2.40% | ₹137 cr |
| SBI ESG Exclusionary Strategy Fund | SBI Mutual Fund | 2.31% | ₹115 cr |
| ADITYA BIRLA SUN LIFE BALANCED ADVANTAGE FUND | Aditya Birla Sun Life Mutual Fund | 1.04% | ₹102 cr |
| Mirae Asset Flexi Cap Fund | Mirae Asset Mutual Fund | 1.72% | ₹75 cr |
| Mirae Asset Great Consumer Fund | Mirae Asset Mutual Fund | 1.60% | ₹71 cr |
| SBI RETIREMENT BENEFIT FUND - AGGRESSIVE PLAN | SBI Mutual Fund | 2.26% | ₹69 cr |
Compared with similar companies
| Company | Price | Market cap | P/E | P/B | ROE | ROCE | Debt/eq. | 1-yr return |
|---|---|---|---|---|---|---|---|---|
| Lenskart Solutions Limited | ₹678.2 | ₹1,17,960 cr | 179 | — | 6.7% | 7.8% | 0.35 | +68.7% |
| Molbio Diagnostics Limited | ₹1,274 | ₹14,689 cr | — | — | 13.8% | 19.2% | 0.3 | +57.9% |
| Poly Medicure Limited | ₹1,449.5 | ₹14,676 cr | 46.7 | — | 11% | 10.9% | 0.11 | -26.5% |
| Standard Engineering Technology Ltd | ₹395.85 | ₹7,885 cr | 92.3 | — | 10.7% | 13.3% | 0.1 | +115.7% |
| Sahajanand Medical Technologies Limited | ₹462.7 | ₹4,675 cr | — | — | — | — | — | +24.7% |
| Virtuoso Optoelectronics Limited | ₹460.2 | ₹1,575 cr | 83.5 | — | 4.3% | -3.5% | 0.84 | +2.3% |
Compare LENSKART with MOLBIO in detail →
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open LENSKART in NSE Scanner →